We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Novel Coronavirus Could Be Targeting Kidneys, Suggests New Data

By HospiMedica International staff writers
Posted on 19 Mar 2020
New data on the coronavirus disease has revealed that kidney involvement appears to be frequent in people who have tested positive and developed symptoms. More...
Proteinuria (and/or blood in urine) often occurs at the beginning or during the infection, with a few patients even developing acute kidney injury (AKI), thus indicating that COVID-19 also attacks the kidneys. Given the involvement of kidneys during coronavirus infection, patients should also be monitored after the disease.

This is based on two studies which showed a high rate of renal abnormalities in corona-positive patients. In the first study, after being admitted to the hospital, 34% of the 59 patients developed massively elevated levels of albumin in urine (proteinuria), a symptom of kidney damage, while 63% of the study patients developed proteinuria while in hospital, and many of them also had blood loss in their urine (hematuria). Kidney function was impaired in 27% of the study population and in 66% of the patients who died from the coronavirus infection. These findings were supported by a second study involving 710 hospitalized patients. Upon admission, 44% of the patients had hematuria and proteinuria (26.7% had only hematuria), while kidney function decreased in nearly 15% of the patients.

“This shows that COVID-19 also attacks the kidneys, not just the lungs,” said Professor Carmine Zoccali, President of the ERA-EDTA (Parma, Italy). “Although the percentage of overall group of COVID-19 infected patients that develop AKI during infection is rather low (about 3-9%), we have to keep in mind that these patients obviously have a poor prognosis. These patients should be treated in accordance with best-practice guidelines in nephrology, which includes supportive management as well as dialysis.”

Continuous Renal Replacement Therapy (CRRT) may also be effective in treating patients with COVID-19 and sepsis syndrome (regardless of their kidney function). On the other hand, patients with chronic kidney disease and especially dialysis patients are at high risk because comorbidities increase the risk of dying from COVID-19.

“Many have already recovered from the disease. AKI patients should be seen regularly by nephrologists, because the risk of these patients developing chronic kidney disease is high. But given the involvement of kidneys during coronavirus infection, we should also monitor those patients who did not develop AKI, but proteinuria and/or hematuria. Otherwise there is a risk that the corona epidemic will be followed by an epidemic of chronic and end-stage kidney disease,” added Zoccali.

Related Links:
ERA-EDTA


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mobile X-Ray System
K4W
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.